September 24, 2015
Kite Pharma to Present at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference
SANTA MONICA, Calif., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that Marc Better Ph.D., Vice President, Product Sciences, will present during the opening plenary session at IBC Life Sciences' IMMUNO-ONCOLOGY: Advancing the Next Generation of Cancer Immunotherapies Conference, taking place in Alexandria, VA, September 30 - October 1, 2015. Dr. Better's presentation, "Overcoming Challenges for Engineered Autologous T Cell Therapy," will take place on Wednesday, September 30, 2015, at 8:15am Eastern Time. In addition, a podcast and article related to Dr. Better's participation in the upcoming event are available via the Calendar of Events section of Kite's website at ir.kitepharma.com.
About Kite Pharma, Inc.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite PharmaCynthia M. Butitta
Chief Financial Officer and Chief Operating Officer
310-824-9999
For Media: Justin Jackson
For Investor Inquiries: Lisa BurnsBurns McClellan
212-213-0006
jjackson@burnsmc.com
lburns@burnsmc.com
Source: Kite Pharma, Inc.News Provided by Acquire Media
